Mark Skolnick

Mark Skolnick
Name	Mark Skolnick
Birth date	1945
Birth place	United States
Fields	Genetics, Molecular Biology, Medical Genetics
Institutions	Myriad Genetics, University of Utah School of Medicine, Washington University in St. Louis, Stanford University
Alma mater	Yeshiva University, Washington University in St. Louis, University of Utah
Known for	BRCA1 cloning, hereditary breast and ovarian cancer genetics

Mark Skolnick is an American geneticist and molecular biologist known for leading the team that cloned the BRCA1 gene and for cofounding Myriad Genetics. He has been associated with institutions including the University of Utah School of Medicine and has contributed to translational genetics, commercial diagnostics, and legal debates over gene patenting. His work intersects with figures, institutions, and events in oncology, molecular biology, biotechnology, intellectual property, and bioethics.

Early life and education

Skolnick grew up in the United States and pursued undergraduate studies at Yeshiva University before completing graduate training at Washington University in St. Louis and postdoctoral work at the University of Utah. During formative years he interacted with researchers connected to Harvard Medical School, Massachusetts General Hospital, National Institutes of Health, Howard Hughes Medical Institute, and laboratories influenced by the work of Francis Crick, James Watson, Rosalind Franklin, and Max Perutz. His academic pathway brought him into contact with clinical genetics groups at the Brigham and Women's Hospital, the Mayo Clinic, and the Cleveland Clinic Foundation, establishing links to broader networks including the American Society of Human Genetics and the National Cancer Institute.

Career and research

Skolnick's research focused on positional cloning, linkage analysis, and mutation screening, applying molecular techniques developed in laboratories such as Cold Spring Harbor Laboratory, Salk Institute, Broad Institute, and Whitehead Institute. He collaborated with investigators affiliated with Stanford University, Johns Hopkins University, University of Pennsylvania, and Columbia University while engaging technologies pioneered at companies like Genentech, Amgen, Biogen, and Celera Genomics. His work built on methods from researchers such as Michael Wigler, Eric Lander, Frederick Sanger, and Kary Mullis and was informed by resources from the Human Genome Project, International HapMap Project, and sequencing centers at Washington University Genome Sequencing Center and the Sanger Centre.

Skolnick's laboratory employed polymorphic marker mapping, large pedigrees, and clinical ascertainment strategies used in studies conducted at Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, Fred Hutchinson Cancer Research Center, and Mount Sinai Hospital. He interacted with oncologists and pathologists from MD Anderson Cancer Center, Royal Marsden Hospital, Guy's and St Thomas' NHS Foundation Trust, and others studying hereditary cancer syndromes, including work on genes such as TP53, PTEN, APC, and MLH1.

Role in genetics of hereditary breast and ovarian cancer

Skolnick led a team that localized and contributed to cloning the BRCA1 locus, a landmark advance in hereditary breast and ovarian cancer genetics that paralleled efforts by groups at The Institute of Cancer Research, University of Cambridge, Columbia University Medical Center, and Thomas Jefferson University. The BRCA1 project engaged collaborators from clinical sites including St. Mary's Hospital, Royal Victoria Hospital, Guy's Hospital, Great Ormond Street Hospital, and international consortia connected to the European Molecular Biology Laboratory.

The discovery of BRCA1 influenced risk assessment, counseling, and management protocols at institutions such as NCI, Centers for Disease Control and Prevention, American College of Medical Genetics and Genomics, and clinics offering prophylactic surgery pioneered by surgeons at Johns Hopkins Hospital and Guy's and St Thomas' NHS Foundation Trust. Skolnick's work intersected with developments in next-generation sequencing technologies from Illumina, Roche, and Thermo Fisher Scientific, and with variant interpretation frameworks advanced by the ClinVar database and guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network.

Legal and commercial activities

Skolnick cofounded Myriad Genetics to commercialize tests for BRCA1 and BRCA2, engaging with biotechnology investors, venture capital firms active in Silicon Valley, Boston, and San Francisco, and legal counsel experienced in patent law practiced before the United States Patent and Trademark Office and litigated in federal courts including the United States Court of Appeals for the Federal Circuit and the Supreme Court of the United States. Myriad's patents and business model prompted litigation involving plaintiffs represented by advocacy groups such as American Civil Liberties Union and debated alongside precedents like Association for Molecular Pathology v. Myriad Genetics, Inc. and decisions referencing Diamond v. Chakrabarty.

Commercialization raised questions debated in venues including the National Academies of Sciences, Engineering, and Medicine, panels at United Nations Educational, Scientific and Cultural Organization, symposia hosted by World Health Organization, and academic commentary from faculty at Harvard Law School, Yale Law School, Stanford Law School, and Columbia Law School. The case influenced biotechnology licensing practices at universities like Stanford University, Massachusetts Institute of Technology, University of California, Berkeley, and University of Pennsylvania.

Awards and honors

Skolnick has been recognized by medical and scientific societies including the American Association for the Advancement of Science, the American Society of Human Genetics, and institutions granting honorary degrees such as Yeshiva University and regional societies in Utah. His work received attention from organizations like Time (magazine), Nature (journal), Science (journal), The New York Times, and professional honors conferred by centers including University of Utah and panels of the National Institutes of Health.

Category:American geneticists Category:Medical researchers Category:Myriad Genetics